Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px
Organisation › Details

Celeris Therapeutics GmbH

Founded in 2020, CelerisTx is a US-Austrian, partially integrated drug discovery company focused on AI-driven development of novel proximity-inducing compounds to enable targeted protein degradation of pathogenic proteins. CelerisTx develops the Celeris One™ platform, a closed-loop development engine that predicts biomolecular interactions, generates new chemical matter that meets relevant degrader success criteria, and extends this knowledge to synthesis and biochemical validation. The application of this development engine promises to streamline the way potent degraders are discovered while increasing productivity in upstream research and development. CelerisTx partners with pharma and biotech companies and develops its drug pipeline in the areas of neurodegenerative diseases and oncology. The offices are located in Menlo Park, California, and Graz, Austria, with laboratory operations to commence in the coming months. *

 

Period Start 2020-01-01 established
  Group Celeris Therapeutics (CelerixTx) (Group)
Products Industry proximity-inducing compounds (PIC™ degrader drugs)
  Industry 2 Celeris One™ platform
Persons Person Trummer, Christopher (Celeris Therapeutics 202202 CEO + Co-Founder)
  Person 2 Hohenberger, Jakob (Celeris Therapeutics 202202 CFO/COO + Co-Founder)
     
Region Region Graz
  Country Austria
  Street 7 Salzamtsgasse
  City 8010 Graz
    Address record changed: 2022-03-05
     
Basic data Employees n. a.
     
    * Document for �About Section�: Celeris Therapeutics GmbH. (2/24/22). "Press Release: CelerisTx Appoints Pharmaceuticals Industry Leader Peter Ho, M.D., Ph.D., to the Board of Directors". Menlo Park, CA.
     
   
Record changed: 2022-03-06

Advertisement

Picture [iito] Fighting Customers 650x100px

More documents for Celeris Therapeutics (CelerixTx) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px




» top